Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice

Gut Pathogens

David Keller³  Sean Farmer³  Kelly D Karpa²  Wallace H Greene¹  Jeffrey S Small²  Leo R Fitzpatrick² 

[1] Department of Pathology, Penn State College of Medicine, PO Box 850, Hershey, PA, 17033, USA;Department of Pharmacology, Penn State College of Medicine, 1214 Research Boulevard, Hummelstown, PA, 17036, USA;Ganeden Biotech Inc., 5800 Landerbrook Drive, Suite 300, Mayfield Heights, OH, 44124, USA

关键词: Mice;    Colitis;    Probiotics;    GanedenBC30;    Clostridium difficile;   

Others  :  821886
DOI  :  10.1186/1757-4749-4-13

 received in 2012-08-08, accepted in 2012-10-12,  发布年份 2012

【 摘 要 】

Background

Recently, we found that the probiotic strain Bacillus coagulans GBI-30, 6086 (GanedenBC³⁰) improved indices of Clostridium difficile (C. difficile)-induced colitis in mice (Fitzpatrick et al., Gut Pathogens, 2011). Our goal was to determine if BC30 could also prevent the recurrence of C. difficile-induced colitis in mice, following initial treatment with vancomycin. During study days 0 through 5, mice were treated with antibiotics. On day 6, the C. difficile strain VPI 10463 was given by oro-gastric gavage at ≈ 5x10⁴ CFU to induce colitis. Mice were treated on study days 6 to 10 with vancomycin (50 mg/kg) (vanco) or vehicle (saline) by gavage. On days 10 to16, mice were dosed by gavage with saline vehicle or BC30 (2 x 10⁹ CFU per day). Mice were monitored for mortality, weight loss and diarrhea. On study days 14, 16 and 17, stools and colons were collected for analyzing other parameters of colitis.

Results

The mean stool consistency score in Vehicle/C.difficile/Vanco mice increased from 0.4 (day 10) to a range of 1.1 to 1.4 (days 14 to 17), indicating the recurrence of colitis. On days 13 through 17, the stool consistency scores for the vancomycin/BC30 mice were significantly lower (p< 0.05) than for the vancomycin/vehicle cohort of animals. On day 17, 88.9% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0004). Colonic myeloperoxidase (Units/2 cm colon) was significantly (p < 0.05) reduced from 4.3 ± 0.7 (Vehicle/C.difficile/Vanco) to 2.6 ± 0.2 (BC30/C. Difficle/Vanco). The colonic histology score and Keratinocyte derived-chemokine level in the colon were also lower in BC30 treated mice.

Summary

In BC30-treated mice, there was evidence of better stool consistency, as well as improved biochemical and histological indices of colitis, following initial treatment of animals with vancomycin.

Conclusion

BC30 limited the recurrence of CD-induced colitis following vancomycin withdrawal in mice.

【 授权许可】

   
2012 Fitzpatrick et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]McDonald LC, Kilgore GE, Thompson A, Owens RC, Kazavoka SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
• [2]Pepin J, Valiquetet L, Alary ME, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C: Clostridium-difficile-associated diarrhea in a region of Quebec from 1991–2003: a changing pattern of disease activity. CMAJ 2004, 171:466-472.
• [3]Johnson S, Gerding DN: Clostridium difficile-associated diarrhea. Clin Infect Dis 1998, 26:1027-1034.
• [4]Kelly CP, Pothoulakis C, Lamont JT: Clostridium difficile colitis. N Eng J Med 1994, 330:257-262.
• [5]Pothoulakis C, Lamont JT: Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Gastrointest Liver Physiol 2001, 28:G178-G183.
• [6]Kim JM, Lee JY, Yoon M, Oh YK, Youn J, Kim YJ: NF-κB activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scand J Gastroenterol 2006, 63:453-460.
• [7]Kim H, Rhee SH, Pothoulakis C, Lamont JT: Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 2007, 133:875-886.
• [8]Lee JY, Park HR, Oh YK, Kim YJ, Youn J, Han JS, Kim JM: Effects of transcription factor activator protein-1 on interleukin-8 expression and enteritis in response to Clostridium difficile toxin A. J Mol Med 2007, 2007(85):1393-1404.
• [9]Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, Pothoulakis C, Lamont JT: Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin-E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem 2005, 280:2137-22545.
• [10]Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP: A mouse model of clostridium difficile-associated disease. Gastroenterology 2008, 135:1984-1992.
• [11]Bartlett JG: Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984, 6(Suppl1):S235-S241.
• [12]Surawicsz C, McFarland LV, Elmer G, Chinn J: Treatment of recurrent clostridium difficile colitis with vancomycin and saccharomyces boulardii. Am J Gastroenterol 1989, 84:1-5.
• [13]McFarland LV, Surawicsz C, Greenberg RN: A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA 1994, 271:1913-1918.
• [14]Surawicsz C, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmaker S, Bowen K, Borjal D, Elmer GW: The search for a better treatment for recurrent clostridium difficile disease: use of high-dose vancomycin combined with saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
• [15]Kimmey MB, Elmer GW, Surawicsz C, McFarland LV: Prevention of further recurrences of clostridium difficile colitis with saccharomyces boulardii. Dig Dis Sci 1990, 35:897-901.
• [16]Keller D, Farmer S, McCartney A, Gibson G: Bacillus coagulans as a probiotic. Food Sci Technol Bull: Funct Foods 2010, 7:103-109.
• [17]Jensen GS, Benson KF, Carter SG, Endres JR: Ganeden BC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010, 11:15. BioMed Central Full Text
• [18]Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Keller D: Bacillus Coagulans GBI-30 (BC30) improves indices of clostridium difficile induced colitis in mice. Gut Pathogens 2011, 3:16. BioMed Central Full Text
• [19]Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H: Mouse relapse model of Clostridium difficile infection. Infect Immun 2011, 79:2856-2864.
• [20]Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB: The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2011, 2:145-158.
• [21]Jefferson KK, Smith MF, Bobak DA: Roles of intracellular calcium and NF-κB in the clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 1999, 165:5183-5191.
• [22]Alcantra C, Stenson WJ, Steiner TS, Guerrant RL: Role of inducible cyclooxygenase and prostaglandin in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J Infect Dis 2001, 184:648-652.
• [23]Fitzpatrick LR, Ludwig D, Hofmann C, Small JS, Groeppel M, Hamm S, Lemstra S, Leban J, Ammendola A: 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflam Bowel Dis 2010, 16:1763-1777.